205 related articles for article (PubMed ID: 31539742)
1. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
3. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
[TBL] [Abstract][Full Text] [Related]
5. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
7. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
8. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
[TBL] [Abstract][Full Text] [Related]
14. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
El-Wakil MH; Teleb M
Bioorg Chem; 2021 Nov; 116():105304. PubMed ID: 34534756
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]